Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 14.35%91.68B | -2.07%25.8B | 6.43%23.88B | 27.23%22.78B | 42.52%19.22B | 16.49%80.17B | 15.70%26.34B | 27.17%22.44B | 21.59%17.91B | -1.46%13.48B |
Cost of revenue | 12.52%80.02B | -4.14%22.05B | 8.23%21.38B | 21.71%19.56B | 38.62%17.03B | 17.83%71.12B | 16.96%23B | 28.58%19.76B | 25.66%16.07B | -1.99%12.29B |
Gross profit | 28.71%11.65B | 12.22%3.75B | -6.89%2.5B | 75.61%3.22B | 82.78%2.19B | 6.98%9.05B | 7.75%3.34B | 17.70%2.69B | -5.32%1.83B | 4.36%1.2B |
Operating expense | 11.47%7.08B | 4.16%2.05B | 30.26%1.83B | 11.20%1.58B | 3.99%1.62B | 2.92%6.35B | 13.86%1.97B | 0.36%1.41B | -3.92%1.42B | -0.45%1.55B |
Staff costs | 13.76%3.18B | ---- | ---- | ---- | ---- | 0.87%2.8B | ---- | ---- | ---- | ---- |
Depreciation and amortization | 12.05%465M | ---- | ---- | ---- | ---- | -4.82%415M | ---- | ---- | ---- | ---- |
-Depreciation | 12.05%465M | ---- | ---- | ---- | ---- | -4.82%415M | ---- | ---- | ---- | ---- |
Other operating expenses | 9.36%3.44B | ---- | ---- | ---- | ---- | 5.97%3.14B | ---- | ---- | ---- | ---- |
Operating profit | 69.26%4.57B | 23.87%1.69B | -47.81%667M | 297.09%1.64B | 259.94%571M | 17.96%2.7B | 0.00%1.37B | 45.39%1.28B | -9.83%413M | 13.77%-357M |
Net non-operating interest income (expenses) | 29.63%-19M | 42.86%-4M | 50.00%-3M | 28.57%-5M | 0.00%-7M | 10.00%-27M | 0.00%-7M | 14.29%-6M | 12.50%-7M | 12.50%-7M |
Non-operating interest income | 250.00%7M | --2M | 200.00%3M | 100.00%2M | --0 | 100.00%2M | --0 | 0.00%1M | --1M | --0 |
Non-operating interest expense | -10.34%26M | -14.29%6M | -14.29%6M | -12.50%7M | 0.00%7M | -6.45%29M | 0.00%7M | -12.50%7M | 0.00%8M | -12.50%7M |
Net investment income | 10.56%314M | 6.25%17M | 11.97%131M | 40.00%14M | 7.80%152M | 5.97%284M | 6.67%16M | 8.33%117M | 25.00%10M | 2.92%141M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -58.84%242M | -61.03%235M | 0 | 16M | 40.00%-9M | 63.33%588M | 67.50%603M | 0 | 0 | -15M |
Income from associates and other participating interests | ||||||||||
Special income (charges) | -102.01%-4M | -140.00%-4M | -100.82%-1M | 200.00%1M | 0 | 313.98%199M | 600.00%10M | 234.07%122M | -1M | 68M |
Less:Other special charges | 101.88%4M | ---- | ---- | ---- | ---- | -21,400.00%-213M | ---12M | ---134M | --1M | ---68M |
Less:Write off | --0 | --0 | ---- | ---- | ---- | -84.78%14M | 100.00%2M | ---- | ---- | ---- |
Other non-operating income (expenses) | 33.33%32M | 0.00%-8M | -44.44%10M | 625.00%29M | -90.00%1M | -65.71%24M | -166.67%-8M | 350.00%18M | -90.91%4M | 0.00%10M |
Income before tax | 36.26%5.13B | -2.73%1.93B | -47.45%804M | 306.71%1.7B | 541.88%707M | 31.58%3.77B | 13.40%1.98B | 71.72%1.53B | -16.77%417M | 41.82%-160M |
Income tax | 10.50%1.42B | -45.08%357M | -43.09%276M | 230.72%549M | 1,693.33%239M | 28.34%1.29B | 11.11%650M | 53.48%485M | -8.29%166M | 81.25%-15M |
Net income | 49.68%3.71B | 18.06%1.57B | -49.47%528M | 358.80%1.15B | 425.00%468M | 33.33%2.48B | 14.47%1.33B | 81.74%1.05B | -21.38%250M | 25.77%-144M |
Net income continuous operations | 49.62%3.71B | 17.97%1.57B | -49.47%528M | 356.97%1.15B | 422.76%468M | 33.32%2.48B | 14.56%1.33B | 81.74%1.05B | -21.56%251M | 25.64%-145M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 49.68%3.71B | 18.06%1.57B | -49.47%528M | 358.80%1.15B | 425.00%468M | 33.33%2.48B | 14.47%1.33B | 81.74%1.05B | -21.38%250M | 25.77%-144M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 49.68%3.71B | 18.06%1.57B | -49.47%528M | 358.80%1.15B | 425.00%468M | 33.33%2.48B | 14.47%1.33B | 81.74%1.05B | -21.38%250M | 25.77%-144M |
Gross dividend payment | ||||||||||
Basic earnings per share | 49.46%144.35 | 17.92%61.01 | -49.63%20.5 | 355.77%44.62 | 422.76%18.22 | 33.11%96.58 | 14.33%51.74 | 81.35%40.695 | -21.40%9.79 | 25.67%-5.645 |
Diluted earnings per share | 49.46%144.35 | 17.94%60.9878 | -49.63%20.5 | 357.95%44.62 | 422.76%18.22 | 33.11%96.58 | 14.29%51.7128 | 81.35%40.695 | -21.55%9.7434 | 25.67%-5.645 |
Dividend per share | 60.00%40 | 60.00%20 | 0 | 60.00%20 | 0 | 0.00%25 | 0.00%12.5 | 0 | 0.00%12.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |